Austin, Texas-based Paradromics develops a high data-rate brain-computer interface (BCI). The company sees its latest financial and regulatory progress as a positive step into the competitive BCI market.
Paradromics plans to use the funding to launch its first-in-human clinical trial for the Connexus direct data interface (DDI).
The Connexus DDI, which received the breakthrough nod, enables communication for people with conditions like ALS, spinal cord injury and stroke. These conditions may cause severe motor impairment, affecting the patients’ ability to communicate.
Connexus DDI’s first application translates brain signals into speech and movement in real time. The assistive communication device restores social connection and ena…